- The Maidenhead plant currently produces Sensodyne and Parodontax products.
- Oral health accounts for approximately one-third of Haleon’s total sales
Haleon, the world’s largest independent provider of consumer healthcare services, is to close its UK production site as part of a cost-cutting exercise that will see hundreds of job losses.
Around 436 jobs will be cut by 2026 following the closure of the Maidenhead plant, which makes oral health brands including Sensodyne toothpaste, a spokesperson confirmed to Reuters news agency.
In an effort to reduce debt since it was spun off by GSK in 2022, Haleon has been on a £300m-a-year cost-savings programme.
It has also been refocusing its portfolio, shedding brands such as Lamisil for fungal nail infections and Chapstick for sore lips.
Haleon products include Sensodyne toothpaste and Panadol pain reliever.
The Haleon spokesperson said the gradual closure of the Maidenhead site, expected to be completed in the second quarter of 2026, is part of the company’s effort to become a more “agile” organization without compromising its growing supply chain. .
They added: “Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead facility is no longer a viable option for the manufacturing of our products.”
Oral health accounts for approximately one-third of Haleon’s total sales. The closure of the Maidenhead facility will see toothpaste production moved to the company’s headquarters in Levice, Slovakia.
Mouthwash production will be moved to a third-party contract manufacturer, with details yet to be announced.
The spokesperson added: ‘Haleon continues to have a substantial presence in the UK as a UK listed company.
“We are investing more than £130 million in a new, world-class, state-of-the-art oral health research and development facility in Weybridge.”
haleon stock They rose 1.84 per cent to 337.40 pence in afternoon trading on Tuesday.
